Chargement en cours...
Clinical Impact of Revised Ciprofloxacin Breakpoint in Patients with Urinary Tract Infections by Enterobacteriaceae
In 2018, the Clinical and Laboratory Standards Institute (CLSI) revised ciprofloxacin (CIP)-susceptible breakpoint for Enterobacteriaceae from ≤1 μg/mL to ≤0.25 μg/mL, based on pharmacokinetic-pharmacodynamic (PK-PD) analysis. However, clinical data supporting the lowered CIP breakpoint are insuffic...
Enregistré dans:
| Publié dans: | Antibiotics (Basel) |
|---|---|
| Auteurs principaux: | , , , , , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
MDPI
2021
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8074352/ https://ncbi.nlm.nih.gov/pubmed/33924153 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/antibiotics10040469 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|